Doctella Facilitates Pre- and Post-hospital Care at Home with
Customizable, Interactive CarePrograms™That Utilize
Patient-reported and Physiological Data
IRVINE, Calif.--(BUSINESS WIRE)--Feb. 11, 2019--
Masimo (NASDAQ:
MASI) announced today the launch of Doctella™, a home-based patient
engagement and remote care automation platform. Doctella provides a
complete end-to-end home care solution, allowing clinicians to create
and manage treatment plans, patient schedules, and patient data flow
using automated, customizable CarePrograms™, home device data
aggregation, and a web-based provider dashboard. CarePrograms are
delivered to patients’ smartphones via an app (available for both iOS®
and Android® devices) and dynamically update based on patient
input, both self-reported data and physiological data collected by
connected monitoring devices.
CarePrograms, configurable via the web-based provider portal, represent
a digital, dynamic, and intelligent upgrade to traditional home care
plans. Data pushed to patients can include coaching, guidance, and
recommendations, such as notifications to remind patients to take
medications, connect monitoring devices, or exercise. In turn, the
Doctella secure cloud pulls and processes data entered manually by
patients – such as patient-reported outcomes and textual responses, with
the ability to provide consent through the app – as well as data
gathered from connected devices, such as the Masimo MightySat™ Rx
fingertip SET® pulse oximeter and the Masimo Rad-97™ rainbow
SET™ Pulse CO-Oximeter®, which can act as a Bluetooth®-based
hub, capable of pulling in data from a variety of Masimo and third-party
devices. Doctella incorporates these data into logic-driven protocols
and algorithms that can be customized to meet the needs of clinicians
and institutions.
The Doctella provider portal allows clinicians to keep track of various
physiological events (such as oxygen desaturations) and behaviors (such
as confirming having taken medication as prescribed) for each patient,
helping clinicians identify when intervention may be needed and how to
prioritize the needs of multiple patients. Through such automation,
institutions can more easily deploy home care monitoring at scale while
helping clinicians remain abreast of important developments in patient
condition. The provider portal can also collect population-level health
data to help clinicians gauge the efficacy of various treatment
protocols and develop new plans using data-driven decisions and strategy.
Peter Pronovost, MD, PhD, Chief Clinical Transformation Officer at
University Hospitals, Ohio, and one of the co-developers of Doctella,
said, “As healthcare seeks to improve value, it needs to change its
narrative from success being patients healing in the hospital to
patients being healthy at home. Doctella helps to accelerate that
journey by making sure that patients receive safe, evidence-based care
in the healing environment of their own home.” Dr. Pronovost recently
spoke about the need to change the healthcare narrative at the 2019
World Patient Safety, Science, and Technology Summit.
Patient monitoring at home is an important and increasingly recognized
part of providing quality patient care. Home care may be beneficial, for
example, for patients with conditions like chronic obstructive pulmonary
disease (COPD) and post-surgical patients recuperating at home using
prescribed opioids. With proper care pre- and post-surgery at home,
patients are expected to do better and help reduce the rate of avoidable
hospital readmissions.
Joe Kiani, Founder and CEO of Masimo, said, “Masimo has always sought
ways to help caring clinicians automate and improve the care of their
patients. Doctella extends our role into perioperative care outside the
hospital and in the home. With customized, automated care plans which
funnel patient data to clinicians while helping them prioritize and
intervene as needed, Doctella brings clinicians and patients together
comprehensively and securely with a complete, end-to-end solution.”
Masimo Doctella will be debuted during the HIMSS19
Conference in Orlando, Florida starting February 11, at Masimo’s
booth 6259. To schedule a meeting or learn more, please contact sales@masimo.com.
@MasimoInnovates |
#Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™
in post-surgical wards, reduce rapid response activations and costs.3-5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 9 of the top 10
hospitals listed in the 2018-19 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect® (MOC-9®) interface, enabling
other companies to augment Root with new features and measurement
capabilities. Masimo is also taking an active leadership role in mHealth
with products such as the Radius-7® wearable patient monitor,
iSpO2® pulse oximeter for smartphones, and the
MightySat™ fingertip pulse oximeter. Additional information about Masimo
and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/evidence/featured-studies/feature/.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States. The use of the trademark Patient SafetyNet is
under license from University HealthSystem Consortium.
References
-
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
-
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
-
Taenzer AH et al. Impact of pulse oximetry surveillance on rescue
events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
-
Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
-
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
-
Estimate: Masimo data on file
- http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Doctella™and CarePrograms™.
These forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo Doctella and CarePrograms,
contribute to positive clinical outcomes and patient safety; risks
related to our belief that Masimo noninvasive medical breakthroughs
provide cost-effective solutions and unique advantages; as well as other
factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"), which
may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190211005206/en/
Source: Masimo
Media:
Masimo
Evan Lamb
949-396-3376
elamb@masimo.com